Lineage Cell Therapeutics, Inc. (LCTX) Operating margin 2016–2025
Lineage Cell Therapeutics, Inc. (LCTX) operating margin by fiscal year — reported operating income divided by reported revenue.
-251.6%FY2025 · since FY2016: -995.6% → -251.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -251.6% | -25.5 pp |
| FY2024 | -226.1% | +50.4 pp |
| FY2023 | -276.5% | -123.3 pp |
| FY2022 | -153.2% | +980.5 pp |
| FY2021 | -1133.6% | +314.7 pp |
| FY2020 | -1448.4% | -342.4 pp |
| FY2019 | -1106.0% | -268.1 pp |
| FY2018 | -837.9% | +287.1 pp |
| FY2017 | -1125.0% | -129.4 pp |
| FY2016 | -995.6% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice